Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy-Reference-Cited by-同舟云学术

Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy

Published:2007-05 Issue:3 Volume:137 Page:216-220
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Pulsoni Alessandro,Starza Irene Della,Frattarelli Natalia,Ghia Emanuela,Carlotti Emanuela,Cavalieri Elena,Matturro Angela,Tempera Settimio,Rambaldi Alessandro,Foà Robin

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2007.06545.x/fullpdf

Reference15 articles.

1. Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma.

2. BCL-2 FAMILY: Regulators of Cell Death

3. Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma.

4. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment

5. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial;The Lancet Haematology;2024-07

2. Does MRD have a role in the management of iNHL?;Hematology;2021-12-10

3. How to manage early-stage follicular lymphoma;Expert Review of Hematology;2020-09-20

4. MRD als Biomarker für die Prognose und zur Steuerung von Therapieentscheidungen;InFo Hämatologie + Onkologie;2020-04

5. Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy;British Journal of Haematology;2019-08-05